Immutep completes patient enrolment for Phase II trial of eftilagimod alpha in metastatic breast cancer
Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment for its Phase II AIPAC-003 clinical trial. This trial aims to assess the efficacy of its investigational agent, eftilagimod alpha (“efti”), in combination with the chemotherapy drug paclitaxel, for individuals with metastatic breast cancer. The trial has […]